Rep. Lisa C. McClain Sells Cytokinetics, Incorporated (NASDAQ:CYTK) Shares

Key Points

• Representative Lisa C. McClain sold between $1,001 and $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on June 17th, as disclosed in a filing on August 13th.
• Cytokinetics reported a quarterly EPS of -$1.12, beating analysts' estimates by $0.22, with revenue increasing significantly year-over-year.
• Wall Street analysts generally have a Moderate Buy rating on Cytokinetics, with a consensus target price of $71.58.

Representative Lisa C. McClain (R-Michigan) recently sold shares of Cytokinetics, Incorporated NASDAQ: CYTK. In a filing disclosed on August 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in Cytokinetics stock on June 17th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
• Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.

Cytokinetics Trading Down 1.4%

CYTK opened at $37.32 on Thursday. Cytokinetics, Incorporated has a twelve month low of $29.31 and a twelve month high of $59.39. The firm has a market capitalization of $4.47 billion, a PE ratio of -7.32 and a beta of 0.64. The firm's 50-day moving average price is $35.59 and its 200 day moving average price is $38.09.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.12) EPS for the quarter, beating analysts' consensus estimates of ($1.34) by $0.22. The business had revenue of $66.77 million during the quarter, compared to analyst estimates of $1.95 million. During the same quarter in the previous year, the company posted ($1.31) EPS. The firm's revenue was up 26727.3% on a year-over-year basis. As a group, analysts predict that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CYTK. Raymond James Financial began coverage on Cytokinetics in a report on Wednesday, July 30th. They issued a "market perform" rating for the company. Wall Street Zen upgraded Cytokinetics from a "strong sell" rating to a "hold" rating in a report on Sunday, August 10th. Mizuho reduced their price target on Cytokinetics from $103.00 to $84.00 and set an "outperform" rating on the stock in a report on Thursday, May 29th. UBS Group lowered their price target on shares of Cytokinetics from $47.00 to $41.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. Finally, Royal Bank Of Canada dropped their price objective on shares of Cytokinetics from $82.00 to $80.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, Cytokinetics has an average rating of "Moderate Buy" and a consensus target price of $71.58.

Insider Transactions at Cytokinetics

In other Cytokinetics news, Director Edward M. Md Kaye sold 3,636 shares of the company's stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $32.10, for a total transaction of $116,715.60. Following the transaction, the director directly owned 29,658 shares in the company, valued at $952,021.80. This represents a 10.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert I. Blum sold 5,000 shares of the firm's stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $36.45, for a total value of $182,250.00. Following the transaction, the chief executive officer owned 388,108 shares of the company's stock, valued at approximately $14,146,536.60. This represents a 1.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,295 shares of company stock worth $1,384,010 in the last ninety days. 2.70% of the stock is owned by company insiders.

Institutional Trading of Cytokinetics

Hedge funds and other institutional investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC lifted its position in Cytokinetics by 723.7% in the second quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 673 shares during the last quarter. Fifth Third Bancorp raised its stake in shares of Cytokinetics by 42.2% in the 1st quarter. Fifth Third Bancorp now owns 981 shares of the biopharmaceutical company's stock valued at $39,000 after acquiring an additional 291 shares during the period. Hantz Financial Services Inc. lifted its holdings in shares of Cytokinetics by 2,872.7% in the 2nd quarter. Hantz Financial Services Inc. now owns 1,308 shares of the biopharmaceutical company's stock worth $43,000 after acquiring an additional 1,264 shares during the last quarter. Parallel Advisors LLC boosted its position in shares of Cytokinetics by 500.5% during the 1st quarter. Parallel Advisors LLC now owns 1,099 shares of the biopharmaceutical company's stock worth $44,000 after purchasing an additional 916 shares during the period. Finally, GAMMA Investing LLC boosted its position in shares of Cytokinetics by 281.0% during the 1st quarter. GAMMA Investing LLC now owns 1,120 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 826 shares during the period.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.